Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19[J]. J Med Virol,2022,94(1):54-62.
[4]
Sriwastava S, Kataria S, Tandon M, et al. Guillain barre syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series[J]. J Neurol Sci,2021,420:117263.
Yuki N, Uncini A. Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism[J]. Muscle Nerve,2014,49(5):629-635.
[9]
Zhang Y, Zhao Y, Wang Y. Prognostic factors of Guillain-Barre syndrome: a 111-case retrospective review[J]. Chin Neurosurg J,2018,4:14.
[10]
Doets A Y, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome[J]. Brain,2018,141(10):2866-2877.
[11]
Leonhard S E, Mandarakas M R, Gondim F, et al. Diagnosis and management of Guillain-Barre syndrome in ten steps[J]. Nat Rev Neurol,2019,15(11):671-683.
[12]
Lleixà C, Martín-Aguilar L, Pascual-Goñi E, et al. Autoantibody screening in Guillain–Barré syndrome[J]. J Neuroinflamm,2021,18(1).
[13]
Yoshikawa K, Kuwahara M, Morikawa M, et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases[J]. Neurology-Neuroimmunology Neuroinflammation,2018,5(6):e501.
[14]
Liu J X, Willison H J, Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles[J]. Invest Ophthalmol Vis Sci,2009,50(7):3226-3232.
[15]
Kaida K, Kamakura K, Ogawa G, et al. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome[J]. Neurology,2008,71(3):196-201.
2023, Vol. 34 
